MOBERG DERMA INTERIM REPORT JANUARY – SEPTEMBER 2011
First profitable quarter and licensing agreement with MedaJANUARY – SEPTEMBER 2011 · Net sales MSEK 35.4 (3.1), an earnings increase of MSEK 32.3 · Research and development expenses MSEK 19.5 (12.9), a cost increase of MSEK 6.5 · Operating loss MSEK -11.4 (-21.2), an improvement of SEK 9.8 · Net loss after tax SEK -10.8 (-22.1), an improvement of MSEK 11.3 · Earnings/loss per share SEK -1.47 (-3.62) · Operating cash flow per share SEK -2.84 (-3.19) JULY – SEPTEMBER 2011 · Net sales MSEK 21.9 (2.3) · Research and development expenses MSEK 5.8 (5.3) ·